{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:44:16Z","timestamp":1790768656359,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Analysis was conducted to compare levodopa\/carbidopa pharmacokinetics and drug\u2010related material in plasma of healthy participants after receiving a continuous infusion of Levodopa\/Carbidopa Intestinal Gel (LCIG) to a continuous subcutaneous infusion of foslevodopa\/foscarbidopa. Study samples were from a randomized, open\u2010label, 2\u2010period crossover study in 20 healthy participants. Participants received either 24\u2010h foslevodopa\/foscarbidopa SC infusion to the abdomen or LCIG delivered for 24\u2009h to the jejunum through a nasogastric tube with jejunal extension. Serial blood samples were collected for PK. Comparability of the LD PK parameters between the two treatment regimens was determined. Selected plasma samples were pooled per treatment group and per time point for metabolite profiling. LC\u2013MS<jats:sup>n<\/jats:sup> was performed using high\u2010resolution mass spectrometry to identify drug\u2010related material across the dosing regimens and time points. The LD PK parameter central values and 90% confidence intervals following the foslevodopa\/foscarbidopa subcutaneous infusion were between 0.8 and 1.25 relative to the LCIG infusion. With LCIG administration, LD, CD, 3\u2010OMD, DHPA, DOPAC, and vanillacetic acid were identified in plasma at early and late time points (0.75 and 24\u2009h); the metabolic profile after administration of foslevodopa\/foscarbidopa demonstrated the same drug\u2010related compounds with the exception of the administered foslevodopa. 3\u2010OMD and vanillacetic acid levels increased over time in both treatment regimens. Relative quantification of LC\u2013MS peak areas showed no major differences in the metabolite profiles. These results indicate that neither the addition of monophosphate prodrug moieties nor SC administration affects the circulating metabolite profile of foslevodopa\/foscarbidopa compared to LCIG.<\/jats:p>","DOI":"10.1002\/prp2.1190","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T12:49:42Z","timestamp":1712753382000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabolite profiling of foslevodopa\/foscarbidopa in plasma of healthy human participants by <scp>LC\u2010HRMS<\/scp> indicates no major differences compared to administration of levodopa\/carbidopa intestinal gel"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-8444","authenticated-orcid":false,"given":"John P.","family":"Savaryn","sequence":"first","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Smith","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-7738","authenticated-orcid":false,"given":"Matthew","family":"Rosebraugh","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Neenan","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Burton","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennan","family":"Marsh","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3649-5673","authenticated-orcid":false,"given":"David","family":"Wagner","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"309","article-title":"Die topische Lokalisation und das Verhalten von Noradrenalin and Dopamin in der Substantia nigra des normalen und Parkinsonkranken Menschen","volume":"75","author":"Hornykiewicz O","year":"1963","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01485901"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1969.00480160015001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196902132800701"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196702162760703"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1975.00490500080010"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1974.00490380076010"},{"issue":"22","key":"e_1_2_12_9_1","first-page":"340","article-title":"2\u2010year experiences with a combination treatment of Parkinsonism with L\u2010dopa and a decarboxylase inhibitor (Benserazid, Ro 4\u20104602)","volume":"124","author":"Birkmayer W","year":"1974","journal-title":"Wien Med Wochenschr"},{"issue":"4","key":"e_1_2_12_10_1","first-page":"167","article-title":"MK 486 and levodopa in treatment of Parkinsonism","volume":"34","author":"Lieberman AN","year":"1973","journal-title":"Dis Nerv Syst"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)90586-2"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197201062860102"},{"key":"e_1_2_12_13_1","first-page":"169","article-title":"Treatment of Parkinson's disease with L\u2010dopa alone or combined with Ro 4\u20104602","volume":"31","author":"Barbeau A","year":"1972","journal-title":"Rev Can Biol"},{"key":"e_1_2_12_14_1","first-page":"55","article-title":"Modification of L\u2010dopa therapy of Parkinsonism by alpha\u2010methyldopa hydrazine (MK\u2010486)","volume":"96","author":"Yahr MD","year":"1971","journal-title":"Trans Am Neurol Assoc"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"e_1_2_12_16_1","first-page":"397","article-title":"Variations in the \"on\u2013off\" effect","volume":"5","author":"Yahr MD","year":"1974","journal-title":"Adv Neurol"},{"key":"e_1_2_12_17_1","first-page":"331","article-title":"The \u201con\u2013off\u201d response to chronic L\u2010DOPA treatment of Parkinsonism","volume":"5","author":"Sweet RD","year":"1974","journal-title":"Adv Neurol"},{"key":"e_1_2_12_18_1","first-page":"203","volume-title":"Current Concepts in the Treatment of Parkinsonism","author":"Duvoisin R","year":"1974"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.24.5.431"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9439-1"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26073"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.03.012"},{"issue":"10","key":"e_1_2_12_23_1","first-page":"880","article-title":"Half a century of L\u2010DOPA","volume":"9","author":"Mena MA","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(96)00149-7"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","unstructured":"YamamotoT HashizumeK YamatodaniA TaniuchiI TodaK WadaH.Plasma\u2010levels of dopamine sulfo\u2010conjugated dopamine and other dopamine metabolites in dogs after oral\u2010administration of L\u2010DOPA. Paper presented at: Japanese Journal of Pharmacology1987.","DOI":"10.1016\/S0021-5198(19)58065-9"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198403000-00002"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.2340\/000155556397101"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600691205"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1972.tb08988.x"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(72)90392-9"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1972134584"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1971.00490010049007"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212813"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.2018"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-34"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00236a004"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.1190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T06:01:49Z","timestamp":1714629709000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.1190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/prp2.1190"],"URL":"https:\/\/doi.org\/10.1002\/prp2.1190","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1190"}}